Mr. Gill is currently the CFO of EndoChoice, a medical device company which provides devices, diagnostics, infection control and imaging for specialists treating a wide range of gastrointestinal diseases. Prior to joining EndoChoice, he served as CFO of INC Research, a clinical research organization.
Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal market.
More articles on devices:
Spine device company stock report — 5 key companies
Smith & Nephew’s 2014 revenue up 2%: 10 things to know
8 key points on Misonix’s 2Q financial report — sales up 36%
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
